Yükleniyor... / Loading...
This is an observational study looking at inherited BRCA testing, tumor genetic profiling, and real-world treatment outcomes in patients with HER2-negative metastatic breast cancer. It was open to adult women who had started first-line chemotherapy for metastatic breast cancer within the past 90 days. It was conducted as an observational study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+58
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Provision of signed, written and dated informed consent. 2. Adult females (according to the age of majority/adulthood as defined by local regulations). 3. Histologically or cytologically confirmed HER2-ve breast cancer with evidence of metastatic disease. 4. Initiated treatment with 1st line systemic cytotoxic chemotherapy (not hormonal therapy) for metastatic breast cancer in the last 90 days and, at that time, are considered to have exhausted hormone therapy options (if HR+ve). Exclusion Criteria: 1. Previous enrolment in this study. 2. Involvement in the planning and/or conduct of this study (applies to both AstraZeneca staff and/or staff at the study site). 3. Current participation in a clinical study with an investigational oncology product. 4. Previous PARPi therapy, including, but not limited to, participation in a previous clinical study that included PARPi therapy. 5. Current commencement of PARPi treatment.